SCHEMBL2276510

SCHEMBL2276510

C[Si](C)(C)OC1(C#N)CCN(C(=O)OCc2ccccc2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
NPSR1 Q6W5P4 2/20 0.48
ALDH1A1 P00352 5/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
ALOX15 P16050 2/20 0.47
GAA P10253 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
HSD17B10 Q99714 1/20 0.45
USP2 O75604 1/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
ENPP2 Q13822 1/20 0.44
ATXN2 Q99700 1/20 0.44
ACACB O00763 1/20 0.44
OPRD1 P41143 1/20 0.43
OPRK1 P41145 1/20 0.43
JAK2 O60674 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25192404 0.93 MEN1 (0.53) MEN1KMT2ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL2081425 0.82 MEN1 (0.48) MEN1KMT2ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL26043855 0.80 MEN1 (0.50) MEN1KMT2ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL26043865 0.80 MEN1 (0.50) MEN1KMT2ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL3271874 0.79 MEN1 (0.51) MEN1KMT2ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL3273460 0.79 MEN1 (0.51) MEN1KMT2ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL5361998 0.78 SMN1; SMN2 (0.50) MEN1KMT2ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL1290934 0.77 MEN1 (0.56) MEN1KMT2ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL15504877 0.77 MEN1 (0.57) MEN1KMT2ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL18130838 0.76 MEN1 (0.44) MEN1KMT2ANPSR1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025096637-A1 SUBSTITUTED ARYL SULFONAMIDES FOR USE AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2025-05-08 WO disclosed
EP-2260031-B1 COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME (US) 2015-10-07 EP disclosed
EP-2260031-B1 COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME (US) 2015-10-07 EP disclosed
US-8716483-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2014-05-06 US disclosed
US-8716483-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2014-05-06 US disclosed
US-20110189192-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME LLC 2011-08-04 US disclosed
EP-2260031-A1 COMPOUNDS THAT ARE ERK INHIBITORS Schering Corporation (US) 2010-12-15 EP disclosed
WO-2009105500-A1 COMPOUNDS THAT ARE ERK INHIBITORS SCHERING CORPORATION (US) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110189192-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MAPK1, MAPK4, MAPK10 MEN1 1520/4885KMT2A 2669/4885NPSR1 3507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.